Pancreatic Cancer Research

ResearcherHospital Clínic de BarcelonaNo recent work listed

Meritxell Gironella

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4437-5181; OpenAlex author ID A5023065458. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 9

  1. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. Co-author DOI 10.1016/j.ebiom.2021.103797↗
  2. MicroRNAs Deregulated in Intraductal Papillary Mucinous Neoplasm Converge on Actin Cytoskeleton-Related Pathways That Are Maintained in Pancreatic Ductal Adeno… Last author DOI 10.3390/cancers13102369↗
  3. MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics. Last author DOI 10.1038/s41389-020-0227-y↗
  4. Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2018.09.016↗
  5. DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. Co-author DOI 10.1136/gutjnl-2018-316128↗
  6. Deciphering microRNA targets in pancreatic cancer using miRComb R package. Last author DOI 10.18632/oncotarget.24034↗
  7. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. First author DOI 10.1007/s00018-017-2579-9↗
  8. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1080/2162402x.2017.1372080↗
  9. Molecular markers in pancreatic cancer diagnosis. First author DOI 10.1016/j.cca.2012.12.025↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elena Vila-Navarro · 5 shared papers, 2017–2021 · strength 0.46
  2. Cristina Fillat Fonts · 4 shared papers, 2018–2020 · strength 0.40
  3. María Vila-Casadesús · 3 shared papers, 2018–2021 · strength 0.34
  4. Giulia Raimondi · 3 shared papers, 2018–2020 · strength 0.31
  5. Elena Fernández-Castañer · 2 shared papers, 2020–2021 · strength 0.25
  6. Maria Rovira-Rigau · 2 shared papers, 2019–2020 · strength 0.22
  7. Juan Iovanna · 3 shared papers, 2017–2020 · strength 0.22
  8. Noemí Manero‐Rupérez · 1 shared paper, 2022 · strength 0.13
  9. Neus Martínez‐Bosch · 1 shared paper, 2022 · strength 0.13
  10. Carmen E. Guerra · 1 shared paper, 2022 · strength 0.13
  11. Alfredo Carrato Mena · 1 shared paper, 2022 · strength 0.13
  12. Laura Visa · 1 shared paper, 2022 · strength 0.13
  13. Pilar Navarro · 1 shared paper, 2022 · strength 0.13
  14. Pablo Garcı́a de Frutos · 1 shared paper, 2022 · strength 0.13
  15. Julie Earl · 1 shared paper, 2022 · strength 0.13
  16. Philippe Soubeyran · 1 shared paper, 2020 · strength 0.11
  17. Jeroni Luna · 1 shared paper, 2019 · strength 0.09
  18. Susana de la Luna · 1 shared paper, 2019 · strength 0.09
  19. Eva Cristina Vaquero · 1 shared paper, 2019 · strength 0.09
  20. Céline Loncle · 1 shared paper, 2017 · strength 0.06
  21. Véronique Secq · 1 shared paper, 2017 · strength 0.06
  22. Raphaël Maréchal · 1 shared paper, 2017 · strength 0.06
  23. Etienne D. Foucher · 1 shared paper, 2017 · strength 0.06
  24. Julie Roques · 1 shared paper, 2017 · strength 0.06
  25. Christian Bressy · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.